Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(56%)
Results Posted
150%(3 trials)

Phase Distribution

Ph phase_3
2
22%
Ph phase_2
4
44%
Ph phase_1
1
11%
Ph phase_4
1
11%

Phase Distribution

1

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(2)

Detailed Status

Active, not recruiting3
Not yet recruiting2
Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 24 (50.0%)
Phase 32 (25.0%)
Phase 41 (12.5%)

Trials by Status

active_not_recruiting333%
not_yet_recruiting222%
completed222%
recruiting222%

Recent Activity

5 active trials
Showing 5 of 9
not_yet_recruiting

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

NCT07555301
active_not_recruitingphase_3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
completedphase_3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685
not_yet_recruitingphase_1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776
recruitingphase_4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07555301

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Not Yet Recruiting
NCT03762850Phase 3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Active Not Recruiting
NCT03493685Phase 3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Completed
NCT07224776Phase 1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Not Yet Recruiting
NCT07219121Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Recruiting
NCT05003986Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Recruiting
NCT05856760Phase 2

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

Completed
NCT05630612Phase 2

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

Active Not Recruiting
NCT04663204Phase 2

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

Active Not Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9